A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and sma...
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
About this item
Full title
Author / Creator
Woyach, J A , Lin, T S , Lucas, M S , Heerema, N , Moran, M E , Cheney, C , Lucas, D M , Wei, L , Caligiuri, M A and Byrd, J C
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Rituximab has modest activity in relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma but is associated with tumor necrosis factor-α (TNF-α) release that can cause CLL proliferation and inhibit apoptosis. We examined whether disruption of TNF-α by etanercept improves response to rituximab in CLL. Eligible patients had previously t...
Alternative Titles
Full title
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_754884527
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_754884527
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2008.385
